Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT02986529
Other study ID # CRC-C1503
Secondary ID
Status Completed
Phase Phase 1
First received December 6, 2016
Last updated February 6, 2018
Start date November 2016
Est. completion date November 2017

Study information

Verified date December 2017
Source Shanghai Greenvalley Pharmaceutical Co., Ltd.
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

To evaluate the Bioavailability for GV-971 capsules of 150 mg, 300mg, and 450mg after administration of single oral doses of 900mg in healthy Male subjects.


Recruitment information / eligibility

Status Completed
Enrollment 15
Est. completion date November 2017
Est. primary completion date February 24, 2017
Accepts healthy volunteers Accepts Healthy Volunteers
Gender Male
Age group 18 Years to 45 Years
Eligibility Inclusion Criteria:

1. Healthy male subjects;

2. Age:=18 and =45 on the date signing informed consent

3. Body mass index (BMI): 18-25 kg/m2 and the weight =50 kg;

4. Subjects are able to understand the study procedures and methods, and willing to strictly comply with the protocol and give written informed consent.

Exclusion Criteria:

A subject will be excluded if the answer to any of the following criteria is "yes"::

1. Clinically significant abnormalities in physical examination and laboratory test results or 12-lead ECG, etc. in screening;

2. Clinically significant abnormalities in Chest X-ray or abdominal B-ultrasound examination

3. Positive serology screen for Hepatitis B( HBsAg), Hepatitis C(HCV), HIV and USR unheated serum reagin test.

4. Smoking more than 10 cigarettes a day, drugs or alcohol abuse within 6 months prior to screening

5. Participation in any investigational drug or medical instrument study within 3months prior to screening, participation in 3 and more than 3 drug tests in a recent year;

6. Serious infection, trauma and major surgery within 4weeks prior to screening;

7. Blood donation of =400 mL or severe blood lose and the volume of blood loss =400 mL within 4 weeks prior to screening, receiving blood transfusion treatment within 8 weeks prior to screening ;

8. Use of any prescription medicine or herbal remedy, over the counter medication or dietary supplements such as vitamin, calcium within 2 weeks prior to screening.

9. Use of heparin, alginic sodium diester , mannose ester within 4 weeks prior to screening;

10. Vegetarian or person with dietary restrictions

11. Subjects able to father a child are unwilling to use highly effective physical form of birth control from the trial period until 3 months after the completion of study.

12. With diseases which could impact on the absorption, distribution, metabolism and excretion (ADME) of study drugs or protocol adherence in the opinion of the investigator (such medical disorder/disease may relate to ccardiovascular, liver, kidney, digestive, immune, blood, endocrine, metabolic, cancer, neuropsychiatric,etc );

13. Subjects may be allergic to GV-971 in the opinion of the investigator.

14. Any other reasons that the subject is not eligible for participation in the study in the opinion of the investigator.

Study Design


Related Conditions & MeSH terms


Intervention

Drug:
GV-971

Placebos


Locations

Country Name City State
China Phase-I Clinical Research Unit at Shanghai Xuhui Center hospital Shanghai Shanghai

Sponsors (1)

Lead Sponsor Collaborator
Shanghai Greenvalley Pharmaceutical Co., Ltd.

Country where clinical trial is conducted

China, 

Outcome

Type Measure Description Time frame Safety issue
Primary Cmax - maximum observed concentration, is obtained directly from the plasma concentration curve 3 days
Primary AUC0-last-the area under the concentration-time curve from zero to the time of the last measurable concentration; computed using the linear trapezoidal rule 3 days
Primary AUC0-8-the area under the concentration-time curve from zero to the infinity, computed as AUC0-8=AUC0-last+Clast/?z (?z is the terminal phase rate constant) 3 days
See also
  Status Clinical Trial Phase
Completed NCT06043739 - Relative Bioavailability and Effect of Food Study With an Oral Mini-tablet Formulation of Filgotinib in Healthy Subjects Phase 1
Completed NCT02557139 - Bioavailability of Belumosudil (KD025) in Healthy Male Subjects Phase 1
Completed NCT02010944 - A Study to Compare How Much Solifenacin Succinate and Mirabegron Reach the Blood When Administered Together as Fixed-dose Combination Tablets and With Single Individual Tablets of the Same Medications at Three Dose Levels Phase 1
Not yet recruiting NCT01136551 - Comparative Bioavailability Study of an Immediate Release and Controlled Release Oral Formulations of Huperzine A N/A
Completed NCT01208155 - Study in Healthy Males to Assess Bioavailability of 4 Different Fostamatinib Tablets Phase 1
Completed NCT04097808 - Impact of the Source and Food Matrices on the Bioavailability of Peptan® (Collagen Peptides) in Healthy Subjects N/A
Active, not recruiting NCT06098001 - Bioavailability Study of Hemp Phenolics N/A
Completed NCT01912144 - Absorption of Phenolic Acids From Coffee in Humans N/A
Completed NCT03915626 - Effect of Heat on Rivastigmine TDS Products Early Phase 1
Completed NCT01448772 - Comparative Bioavailability of Dronabinol Oral Solution Versus Branded Capsule 5 mg Under Fasting Conditions Phase 1
Completed NCT01464450 - Pharmacokinetics Study of Oral Rivaroxaban in Healthy Participants Phase 1
Completed NCT01181973 - Safety, Tolerability and Relative Bioavailability of Pegvisomant in Healthy Subjects Phase 1
Completed NCT00858767 - Arabic Gum-Absorption Study N/A
Completed NCT04113564 - Absolute Oral Bioavailability of Remimazolam Phase 1
Completed NCT04645394 - Bioavailability of Anthocyanins From Aronia Extract in Healthy Men - a Pilot Study N/A
Completed NCT03485885 - Bioavailability of Maqui Berry Extract (MBE) in Healthy Subjects
Completed NCT05840848 - Effect of Iron and Zinc Supplementation on B-carotene Bioavailability in Healthy Males N/A
Completed NCT01789359 - Urinary Excretion of Anthocyanins During Long Term Blueberry Feeding N/A
Completed NCT01638143 - Bio-equivalence Study N/A
Completed NCT00755872 - Assess the Influence of a High-fat Meal on the Relative Bioavailability Of Two Formulations of Risedronate Phase 1